Pfizer recently announced it decided to discontinue clinical trials of its oral GLP-1 medication for weight loss, called danuglipron, after a study participant experienced a liver injury that was potentially linked to the experimental drug
However, the plaintiff alleges that merely increasing the amount of GLP-1 in the body does not help achieve weight loss, because GLP-1 has such a short half-life at only about two minutes. Despite ongoing litigation, Waldstein noted that only one company to date has received an FDA warning letter for making false and misleading claims related to semaglutide, comparing its GLP-1 support supplement to the drug
Many telehealth platforms have discounted in-network pricing
Which one has stronger data
DSIP plays a role in regulating the endocrine system, which is responsible for hormone production and balance
What time of day should I inject retatrutide